查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1344398

二尖瓣疾病治疗药物市场:依药物类别、年龄层、通路2023-2032 年全球机会分析与产业预测

Mitral Valve Disease Therapeutics Market By Drug class, By Age group, By Distribution channel : Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 268 Pages | 商品交期: 2-3个工作天内

价格

根据Allied Market Research发布的最新报告"二尖瓣疾病治疗药物市场"，2022年二尖瓣疾病治疗药物市场价值为6.0774亿美元，复合年增长率预计为2.8%到2032 年将达到8.034亿美元。

二尖瓣疾病治疗市场-IMG1

推动二尖瓣疾病治疗市场成长的主要因素是二尖瓣疾病盛行率的增加。 越来越多的患者被诊断出患有二尖瓣疾病，例如二尖瓣闭锁不全、二尖瓣脱垂和二尖瓣狭窄。 例如，根据2022 年临床医学杂誌，二尖瓣关闭不全是欧洲第二常见的心臟瓣膜疾病，也是美国最常见的心臟瓣膜疾病，在 75 岁及以上人群中盛行率为 9.3%。 因此，二尖瓣疾病的盛行率不断增加导致对治疗药物的需求并推动市场成长。

此外，二尖瓣疾病可由风湿热、先天性心臟病等多种因素引起。 风湿热是链球菌感染后发生的一种发炎性疾病，发炎可以扩散到心臟并损害心臟瓣膜，包括二尖瓣。 因此，这种损害会导致二尖瓣疾病，引起呼吸急促、疲劳、胸痛和心悸等症状。 此外，先天性心臟病是一种从出生就存在的结构异常。 一些先天性心臟缺陷会影响二尖瓣的功能并引起二尖瓣疾病。 因此，BETA-受体阻断剂、利尿剂和钙通道阻断剂等治疗药物被用来控制二尖瓣疾病的症状，进而推动市场成长。

此外，二尖瓣置换手术数量的增加和治疗药物的采用预计将推动市场成长。 例如，抗凝血剂通常用于治疗二尖瓣疾病并预防可能导致中风等严重併发症的血栓。 因此，抗凝血剂的采用不断增加，推动了市场的成长。

此外，二尖瓣疾病发生率的增加是由于多种因素造成的，包括人口老化以及高血压、糖尿病和肥胖等危险因子的增加。 随着人口老化，罹患二尖瓣疾病的风险增加。 这是因为阀门随着时间的推移会损坏或减弱，从而更容易发生故障。 此外，高血压和肥胖等危险因子的增加也会增加二尖瓣疾病的风险。 此外，患者和医疗保健专业人员对二尖瓣疾病的认识不断提高，导致了早期诊断和治疗，从而推动了对医疗干预措施的需求。 世界各国政府正在投资研究和开发二尖瓣疾病的新疗法，这正在推动新疗法的开发。

目录

第一章简介

第 2 章执行摘要

第三章市场概述

  • 市场定义和范围
  • 主要发现
    • 影响因素
    • 主要投资机会
  • 波特五力分析
  • 市场动态
    • 促进因素
      • 二尖瓣疾病的盛行率不断上升
      • 越来越多地采用药物来控制二尖瓣疾病症状
      • 老年人口增加
    • 抑制因素
      • 替代疗法的可用性
    • 机会
      • 新兴市场的成长机会
  • 新冠肺炎 (COVID-19) 造成的市场影响分析

第 4 章二尖瓣疾病治疗药物市场:依药物类别划分

  • BETA受体阻断剂
  • 利尿剂
  • 抗凝血剂
  • 其他

第五章二尖瓣疾病治疗药物市场:依年龄层

  • 55岁以下
  • 55岁以上

第六章二尖瓣疾病治疗药物市场:依通路划分

  • 医院药房
  • 药局和零售药局
  • 线上提供者

第七章二尖瓣疾病治疗药物市场:依地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 韩国
    • 其他亚太地区
  • 拉丁美洲/中东/非洲
    • 巴西
    • 沙乌地阿拉伯
    • 南非
    • 其他领域

第八章竞争态势

  • 简介
  • 关键成功策略
  • 10家主要公司的产品图谱
  • 竞争对手仪表板
  • 竞争热图
  • 2022 年主要公司的定位

第九章公司简介

  • Zydus Lifesciences Limited
  • Pfizer Inc.
  • Bayer AG
  • Novartis AG
  • Viatris Inc.
  • Alembic Ltd
  • Sun Pharmaceutical Industries Limited
  • Cipla Ltd
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
Product Code: A74639

According to a new report published by Allied Market Research, titled, "Mitral Valve Disease Therapeutics Market," The mitral valve disease therapeutics market was valued at $607.74 million in 2022, and is estimated to reach $803.4 million by 2032, growing at a CAGR of 2.8% from 2023 to 2032.

Mitral Valve Disease Therapeutics Market - IMG1

The major factor driving the growth of the mitral valve disease therapeutics market is increase in prevalence of mitral valve conditions. There has been an increase in the number of patients diagnosed with mitral valve diseases such as mitral regurgitation, mitral prolapse, and mitral stenosis. For instance, Journal of Clinical Medicine 2022, stated that, mitral regurgitation is the second most common valvular heart disease in Europe and the most common in the U.S., with a prevalence of 9.3% in the population aged over 75 years. Thus, rise in prevalence of mitral valve conditions results in demand for therapeutics and propels the market growth.

Further, mitral valve disease can be caused by various factors, such as rheumatic fever and congenital heart defects. Rheumatic fever is an inflammatory disease that can occur after a streptococcal infection, leading to inflammation that can spread to the heart, causing damage to the heart valves, including the mitral valve. Thus, this damage can lead to mitral valve disease, which can cause symptoms such as shortness of breath, fatigue, chest pain, and heart palpitations. In addition, congenital heart defects are structural abnormalities that are present at birth. Some congenital heart defects can affect the function of the mitral valve, leading to mitral valve disease. Thus, to manage the symptoms of mitral valve disease, therapeutics such as beta blockers, diuretics, and calcium channel blockers are prescribed, thereby driving the growth of the market.

Furthermore, rise in mitral valve replacement procedures and adoption of therapeutics is expected to propel the market growth. For instance, anticoagulants are commonly used to manage mitral valve disease and prevent blood clots, which can lead to serious complications such as stroke. Thus, rise in adoption of anticoagulants drives the market growth.

Further, rise in the incidence of mitral valve diseases can be attributed to several factors, such as aging population and increase in risk factors such as high blood pressure, diabetes, and obesity. As the population ages, the risk of developing mitral valve disease increases. This is because the valve can become damaged or weakened over time, making it more prone to malfunction. In addition, the rise in risk factors such as high blood pressure and obesity can increase the risk of developing mitral valve disease. Moreover, rise in awareness of mitral valve diseases among patients and healthcare professionals has led to earlier diagnosis and treatment, driving demand for medical interventions. Governments around the world are investing in research and development of new treatments for mitral valve disease, which has led to the development of novel therapeutics.

In addition, increased awareness about the symptoms and risk factors associated with mitral valve disease has led to more people seeking medical treatment for the condition, which has further driven the growth of the market. However, availability of other treatment options for mitral valve disease is expected to restrain the growth of mitral valve disease therapeutics market. There are several alternative treatment options available for mitral valve disease, such as surgical interventions and transcatheter procedures. These alternative options may be preferred by some patients or may be recommended by healthcare providers based on individual patient needs, thus restraining the growth of market.

The global mitral valve disease therapeutics market is segmented into drug class, age group, distribution channel, and region. On the basis of drug class, the market is categorized into beta blockers, diuretics, anticoagulants, and others. As per age group, the market is categorized into below 55 years and above 55 years. According to distribution channel, the market is segregated into hospital pharmacies, drug stores and retail pharmacies, and online providers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the global mitral valve disease therapeutics market are Zydus Lifesciences Limited, Pfizer Inc., Bayer AG, Novartis AG, Viatris Inc., Alembic Ltd., Teva Pharmaceutical Industries Ltd., Cipla Ltd., Sun Pharmaceutical Industries Limited, and Sanofi.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the mitral valve disease therapeutics market analysis from 2022 to 2032 to identify the prevailing mitral valve disease therapeutics market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the mitral valve disease therapeutics market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global mitral valve disease therapeutics market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Distribution channel

  • Hospital pharmacies
  • Drug store and retail pharmacies
  • Online providers

By Drug class

  • Beta blockers
  • Diuretics
  • Anticoagulants
  • Others

By Age group

  • Below 55 years
  • Above 55 years

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Bayer AG
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd.
    • Pfizer Inc.
    • Viatris Inc.
    • Sun Pharmaceutical Industries Limited
    • Cipla Ltd
    • Zydus Lifesciences Limited
    • Sanofi
    • Alembic Ltd

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Bargaining power of suppliers
    • 3.3.2. Bargaining power of buyers
    • 3.3.3. Threat of substitutes
    • 3.3.4. Threat of new entrants
    • 3.3.5. Intensity of rivalry
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Increasing prevalence of mitral valve diseases
      • 3.4.1.2. Rise in adoption of pharmaceutical drugs to manage mitral valve disease symptoms
      • 3.4.1.3. Rise in geriatric population
    • 3.4.2. Restraints
      • 3.4.2.1. Availability of alternative treatment options
    • 3.4.3. Opportunities
      • 3.4.3.1. Growth opportunities in emerging markets
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Beta blockers
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Diuretics
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Anticoagulants
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country
  • 4.5. Others
    • 4.5.1. Key market trends, growth factors and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market share analysis by country

CHAPTER 5: MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Below 55 years
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Above 55 years
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country

CHAPTER 6: MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospital pharmacies
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Drug store and retail pharmacies
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Online providers
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key trends and opportunities
    • 7.2.2. Market size and forecast, by Drug class
    • 7.2.3. Market size and forecast, by Age group
    • 7.2.4. Market size and forecast, by Distribution channel
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Key market trends, growth factors and opportunities
      • 7.2.5.1.2. Market size and forecast, by Drug class
      • 7.2.5.1.3. Market size and forecast, by Age group
      • 7.2.5.1.4. Market size and forecast, by Distribution channel
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Key market trends, growth factors and opportunities
      • 7.2.5.2.2. Market size and forecast, by Drug class
      • 7.2.5.2.3. Market size and forecast, by Age group
      • 7.2.5.2.4. Market size and forecast, by Distribution channel
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Key market trends, growth factors and opportunities
      • 7.2.5.3.2. Market size and forecast, by Drug class
      • 7.2.5.3.3. Market size and forecast, by Age group
      • 7.2.5.3.4. Market size and forecast, by Distribution channel
  • 7.3. Europe
    • 7.3.1. Key trends and opportunities
    • 7.3.2. Market size and forecast, by Drug class
    • 7.3.3. Market size and forecast, by Age group
    • 7.3.4. Market size and forecast, by Distribution channel
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Key market trends, growth factors and opportunities
      • 7.3.5.1.2. Market size and forecast, by Drug class
      • 7.3.5.1.3. Market size and forecast, by Age group
      • 7.3.5.1.4. Market size and forecast, by Distribution channel
      • 7.3.5.2. France
      • 7.3.5.2.1. Key market trends, growth factors and opportunities
      • 7.3.5.2.2. Market size and forecast, by Drug class
      • 7.3.5.2.3. Market size and forecast, by Age group
      • 7.3.5.2.4. Market size and forecast, by Distribution channel
      • 7.3.5.3. UK
      • 7.3.5.3.1. Key market trends, growth factors and opportunities
      • 7.3.5.3.2. Market size and forecast, by Drug class
      • 7.3.5.3.3. Market size and forecast, by Age group
      • 7.3.5.3.4. Market size and forecast, by Distribution channel
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Key market trends, growth factors and opportunities
      • 7.3.5.4.2. Market size and forecast, by Drug class
      • 7.3.5.4.3. Market size and forecast, by Age group
      • 7.3.5.4.4. Market size and forecast, by Distribution channel
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Key market trends, growth factors and opportunities
      • 7.3.5.5.2. Market size and forecast, by Drug class
      • 7.3.5.5.3. Market size and forecast, by Age group
      • 7.3.5.5.4. Market size and forecast, by Distribution channel
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Key market trends, growth factors and opportunities
      • 7.3.5.6.2. Market size and forecast, by Drug class
      • 7.3.5.6.3. Market size and forecast, by Age group
      • 7.3.5.6.4. Market size and forecast, by Distribution channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key trends and opportunities
    • 7.4.2. Market size and forecast, by Drug class
    • 7.4.3. Market size and forecast, by Age group
    • 7.4.4. Market size and forecast, by Distribution channel
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Key market trends, growth factors and opportunities
      • 7.4.5.1.2. Market size and forecast, by Drug class
      • 7.4.5.1.3. Market size and forecast, by Age group
      • 7.4.5.1.4. Market size and forecast, by Distribution channel
      • 7.4.5.2. China
      • 7.4.5.2.1. Key market trends, growth factors and opportunities
      • 7.4.5.2.2. Market size and forecast, by Drug class
      • 7.4.5.2.3. Market size and forecast, by Age group
      • 7.4.5.2.4. Market size and forecast, by Distribution channel
      • 7.4.5.3. India
      • 7.4.5.3.1. Key market trends, growth factors and opportunities
      • 7.4.5.3.2. Market size and forecast, by Drug class
      • 7.4.5.3.3. Market size and forecast, by Age group
      • 7.4.5.3.4. Market size and forecast, by Distribution channel
      • 7.4.5.4. Australia
      • 7.4.5.4.1. Key market trends, growth factors and opportunities
      • 7.4.5.4.2. Market size and forecast, by Drug class
      • 7.4.5.4.3. Market size and forecast, by Age group
      • 7.4.5.4.4. Market size and forecast, by Distribution channel
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Key market trends, growth factors and opportunities
      • 7.4.5.5.2. Market size and forecast, by Drug class
      • 7.4.5.5.3. Market size and forecast, by Age group
      • 7.4.5.5.4. Market size and forecast, by Distribution channel
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Key market trends, growth factors and opportunities
      • 7.4.5.6.2. Market size and forecast, by Drug class
      • 7.4.5.6.3. Market size and forecast, by Age group
      • 7.4.5.6.4. Market size and forecast, by Distribution channel
  • 7.5. LAMEA
    • 7.5.1. Key trends and opportunities
    • 7.5.2. Market size and forecast, by Drug class
    • 7.5.3. Market size and forecast, by Age group
    • 7.5.4. Market size and forecast, by Distribution channel
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Key market trends, growth factors and opportunities
      • 7.5.5.1.2. Market size and forecast, by Drug class
      • 7.5.5.1.3. Market size and forecast, by Age group
      • 7.5.5.1.4. Market size and forecast, by Distribution channel
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Key market trends, growth factors and opportunities
      • 7.5.5.2.2. Market size and forecast, by Drug class
      • 7.5.5.2.3. Market size and forecast, by Age group
      • 7.5.5.2.4. Market size and forecast, by Distribution channel
      • 7.5.5.3. South Africa
      • 7.5.5.3.1. Key market trends, growth factors and opportunities
      • 7.5.5.3.2. Market size and forecast, by Drug class
      • 7.5.5.3.3. Market size and forecast, by Age group
      • 7.5.5.3.4. Market size and forecast, by Distribution channel
      • 7.5.5.4. Rest of LAMEA
      • 7.5.5.4.1. Key market trends, growth factors and opportunities
      • 7.5.5.4.2. Market size and forecast, by Drug class
      • 7.5.5.4.3. Market size and forecast, by Age group
      • 7.5.5.4.4. Market size and forecast, by Distribution channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

  • 9.1. Zydus Lifesciences Limited
    • 9.1.1. Company overview
    • 9.1.2. Key Executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
  • 9.2. Pfizer Inc.
    • 9.2.1. Company overview
    • 9.2.2. Key Executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
  • 9.3. Bayer AG
    • 9.3.1. Company overview
    • 9.3.2. Key Executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
  • 9.4. Novartis AG
    • 9.4.1. Company overview
    • 9.4.2. Key Executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
  • 9.5. Viatris Inc.
    • 9.5.1. Company overview
    • 9.5.2. Key Executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
  • 9.6. Alembic Ltd
    • 9.6.1. Company overview
    • 9.6.2. Key Executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
  • 9.7. Sun Pharmaceutical Industries Limited
    • 9.7.1. Company overview
    • 9.7.2. Key Executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
  • 9.8. Cipla Ltd
    • 9.8.1. Company overview
    • 9.8.2. Key Executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
  • 9.9. Teva Pharmaceutical Industries Ltd.
    • 9.9.1. Company overview
    • 9.9.2. Key Executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
  • 9.10. Sanofi
    • 9.10.1. Company overview
    • 9.10.2. Key Executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance

LIST OF TABLES

  • TABLE 01. GLOBAL MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 02. MITRAL VALVE DISEASE THERAPEUTICS MARKET FOR BETA BLOCKERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. MITRAL VALVE DISEASE THERAPEUTICS MARKET FOR DIURETICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. MITRAL VALVE DISEASE THERAPEUTICS MARKET FOR ANTICOAGULANTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. MITRAL VALVE DISEASE THERAPEUTICS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 06. GLOBAL MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 07. MITRAL VALVE DISEASE THERAPEUTICS MARKET FOR BELOW 55 YEARS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 08. MITRAL VALVE DISEASE THERAPEUTICS MARKET FOR ABOVE 55 YEARS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 09. GLOBAL MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 10. MITRAL VALVE DISEASE THERAPEUTICS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. MITRAL VALVE DISEASE THERAPEUTICS MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. MITRAL VALVE DISEASE THERAPEUTICS MARKET FOR ONLINE PROVIDERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. NORTH AMERICA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 15. NORTH AMERICA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 17. NORTH AMERICA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 18. U.S. MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 19. U.S. MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 20. U.S. MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 21. CANADA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 22. CANADA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 23. CANADA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 24. MEXICO MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 25. MEXICO MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 26. MEXICO MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 27. EUROPE MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 28. EUROPE MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 29. EUROPE MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 30. EUROPE MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 31. GERMANY MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 32. GERMANY MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 33. GERMANY MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 34. FRANCE MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 35. FRANCE MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 36. FRANCE MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 37. UK MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 38. UK MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 39. UK MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 40. ITALY MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 41. ITALY MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 42. ITALY MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 43. SPAIN MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 44. SPAIN MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 45. SPAIN MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 46. REST OF EUROPE MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 47. REST OF EUROPE MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 48. REST OF EUROPE MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 49. ASIA-PACIFIC MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 50. ASIA-PACIFIC MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 51. ASIA-PACIFIC MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 52. ASIA-PACIFIC MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 53. JAPAN MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 54. JAPAN MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 55. JAPAN MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 56. CHINA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 57. CHINA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 58. CHINA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 59. INDIA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 60. INDIA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 61. INDIA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 62. AUSTRALIA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 63. AUSTRALIA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 64. AUSTRALIA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 65. SOUTH KOREA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 66. SOUTH KOREA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 67. SOUTH KOREA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 68. REST OF ASIA-PACIFIC MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 69. REST OF ASIA-PACIFIC MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 70. REST OF ASIA-PACIFIC MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 71. LAMEA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 72. LAMEA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 73. LAMEA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 74. LAMEA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 75. BRAZIL MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 76. BRAZIL MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 77. BRAZIL MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 78. SAUDI ARABIA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 79. SAUDI ARABIA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 80. SAUDI ARABIA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 81. SOUTH AFRICA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 82. SOUTH AFRICA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 83. SOUTH AFRICA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 84. REST OF LAMEA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
  • TABLE 85. REST OF LAMEA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
  • TABLE 86. REST OF LAMEA MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 87. ZYDUS LIFESCIENCES LIMITED: KEY EXECUTIVES
  • TABLE 88. ZYDUS LIFESCIENCES LIMITED: COMPANY SNAPSHOT
  • TABLE 89. ZYDUS LIFESCIENCES LIMITED: PRODUCT SEGMENTS
  • TABLE 90. ZYDUS LIFESCIENCES LIMITED: PRODUCT PORTFOLIO
  • TABLE 91. PFIZER INC.: KEY EXECUTIVES
  • TABLE 92. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 93. PFIZER INC.: PRODUCT SEGMENTS
  • TABLE 94. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 95. BAYER AG: KEY EXECUTIVES
  • TABLE 96. BAYER AG: COMPANY SNAPSHOT
  • TABLE 97. BAYER AG: PRODUCT SEGMENTS
  • TABLE 98. BAYER AG: PRODUCT PORTFOLIO
  • TABLE 99. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 100. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 101. NOVARTIS AG: PRODUCT SEGMENTS
  • TABLE 102. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 103. VIATRIS INC.: KEY EXECUTIVES
  • TABLE 104. VIATRIS INC.: COMPANY SNAPSHOT
  • TABLE 105. VIATRIS INC.: PRODUCT SEGMENTS
  • TABLE 106. VIATRIS INC.: PRODUCT PORTFOLIO
  • TABLE 107. ALEMBIC LTD: KEY EXECUTIVES
  • TABLE 108. ALEMBIC LTD: COMPANY SNAPSHOT
  • TABLE 109. ALEMBIC LTD: PRODUCT SEGMENTS
  • TABLE 110. ALEMBIC LTD: PRODUCT PORTFOLIO
  • TABLE 111. SUN PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES
  • TABLE 112. SUN PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
  • TABLE 113. SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT SEGMENTS
  • TABLE 114. SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
  • TABLE 115. CIPLA LTD: KEY EXECUTIVES
  • TABLE 116. CIPLA LTD: COMPANY SNAPSHOT
  • TABLE 117. CIPLA LTD: PRODUCT SEGMENTS
  • TABLE 118. CIPLA LTD: PRODUCT PORTFOLIO
  • TABLE 119. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 120. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 121. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
  • TABLE 122. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 123. SANOFI: KEY EXECUTIVES
  • TABLE 124. SANOFI: COMPANY SNAPSHOT
  • TABLE 125. SANOFI: PRODUCT SEGMENTS
  • TABLE 126. SANOFI: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. MITRAL VALVE DISEASE THERAPEUTICS MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF MITRAL VALVE DISEASE THERAPEUTICS MARKET, 2022-2032
  • FIGURE 03. TOP INVESTMENT POCKETS IN MITRAL VALVE DISEASE THERAPEUTICS MARKET (2023-2032)
  • FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. LOW BARGAINING POWER OF BUYERS
  • FIGURE 06. LOW THREAT OF SUBSTITUTES
  • FIGURE 07. LOW THREAT OF NEW ENTRANTS
  • FIGURE 08. LOW INTENSITY OF RIVALRY
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALMITRAL VALVE DISEASE THERAPEUTICS MARKET
  • FIGURE 10. MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2022(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF MITRAL VALVE DISEASE THERAPEUTICS MARKET FOR BETA BLOCKERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF MITRAL VALVE DISEASE THERAPEUTICS MARKET FOR DIURETICS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF MITRAL VALVE DISEASE THERAPEUTICS MARKET FOR ANTICOAGULANTS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF MITRAL VALVE DISEASE THERAPEUTICS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 15. MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY AGE GROUP, 2022(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF MITRAL VALVE DISEASE THERAPEUTICS MARKET FOR BELOW 55 YEARS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF MITRAL VALVE DISEASE THERAPEUTICS MARKET FOR ABOVE 55 YEARS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 18. MITRAL VALVE DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2022(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF MITRAL VALVE DISEASE THERAPEUTICS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF MITRAL VALVE DISEASE THERAPEUTICS MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF MITRAL VALVE DISEASE THERAPEUTICS MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 22. MITRAL VALVE DISEASE THERAPEUTICS MARKET BY REGION, 2022
  • FIGURE 23. U.S. MITRAL VALVE DISEASE THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 24. CANADA MITRAL VALVE DISEASE THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 25. MEXICO MITRAL VALVE DISEASE THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 26. GERMANY MITRAL VALVE DISEASE THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 27. FRANCE MITRAL VALVE DISEASE THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. UK MITRAL VALVE DISEASE THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. ITALY MITRAL VALVE DISEASE THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. SPAIN MITRAL VALVE DISEASE THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. REST OF EUROPE MITRAL VALVE DISEASE THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. JAPAN MITRAL VALVE DISEASE THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. CHINA MITRAL VALVE DISEASE THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. INDIA MITRAL VALVE DISEASE THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. AUSTRALIA MITRAL VALVE DISEASE THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. SOUTH KOREA MITRAL VALVE DISEASE THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. REST OF ASIA-PACIFIC MITRAL VALVE DISEASE THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. BRAZIL MITRAL VALVE DISEASE THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. SAUDI ARABIA MITRAL VALVE DISEASE THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 40. SOUTH AFRICA MITRAL VALVE DISEASE THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 41. REST OF LAMEA MITRAL VALVE DISEASE THERAPEUTICS MARKET, 2022-2032 ($MILLION)
  • FIGURE 42. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 43. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 44. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 45. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 46. COMPETITIVE DASHBOARD
  • FIGURE 47. COMPETITIVE HEATMAP: MITRAL VALVE DISEASE THERAPEUTICS MARKET
  • FIGURE 48. TOP PLAYER POSITIONING, 2022
  • FIGURE 49. ZYDUS LIFESCIENCES LIMITED: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 50. ZYDUS LIFESCIENCES LIMITED: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 51. ZYDUS LIFESCIENCES LIMITED: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 52. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 53. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 54. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 55. BAYER AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 56. BAYER AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 57. BAYER AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 58. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 59. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 60. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 61. VIATRIS INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 62. VIATRIS INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 63. ALEMBIC LTD: SALES REVENUE, 2020-2022 ($MILLION)
  • FIGURE 64. ALEMBIC LTD: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 65. ALEMBIC LTD: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 66. SUN PHARMACEUTICAL INDUSTRIES LIMITED: SALES REVENUE, 2020-2022 ($MILLION)
  • FIGURE 67. SUN PHARMACEUTICAL INDUSTRIES LIMITED: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 68. CIPLA LTD: SALES REVENUE, 2020-2022 ($MILLION)
  • FIGURE 69. CIPLA LTD: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 70. CIPLA LTD: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 71. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 72. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 73. SANOFI S.A.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 74. SANOFI S.A.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 75. SANOFI S.A.: REVENUE SHARE BY REGION, 2022 (%)